Johnson & Johnson to Initiate Harvard-Originated Experimental HIV Vaccine Clinical Trial Later in 2019

HIV Vaccine Clinical Trial

Called a tetravalent mosaic, Johnson & Johnson (J&J) will initiate an experimental HIV vaccine in the U.S. and Europe in a move toward introducing the first immunization against the deadly disease.  3,800 targeted participants (males who have sex with males) will receive the regimen of injections in the study planned for later in 2019. The U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network of testing sites will be collaborating with the U.S. pharma’s Janssen unit.
Published in Bloomberg by John Lauerman, we note that investigators have yet to develop a vaccine against the deadly disease that still takes nearly 1 million lives worldwide per year.
Janssen Target
The unit of J&J seeks to develop a vaccine that can work in a diverse range of population worldwide infected with multiple strains of the rapidly changing virus. Dan Barouch, a Harvard Medical School professor whose research made the vaccine possible, noted that the approach “brings us one step closer to covering the vast diversity of viruses worldwide.”  He continued, “For medical and global public health reasons, it’s better to have a vaccine that works in mu...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee